<DOC>
	<DOCNO>NCT03028701</DOCNO>
	<brief_summary>The overall objective ass bronchodilator effect single dose Formoterol/Budesonide 12/400 mcg fix combination deliver via Discair® patient COPD . Spirometric measurement ( FEV1 , FVC ) perform period 12 h 12 different time : pretreatment ( prior first dose ) posttreatment ( 15. min , 30. min , 1 hr , 2 hr , 3 hr , 4 hr , 5 hr , 6 hr , 8 hr , 10 hr 12 hr ) .</brief_summary>
	<brief_title>Assessment Bronchodilator Efficacy Formoterol/Budesonide 12/400 mcg Via Discair COPD</brief_title>
	<detailed_description>The overall objective ass bronchodilator effect single dose Formoterol/Budesonide 12/400 mcg fix dose combination deliver via Discair® patient COPD . Patients assign receive single dose Formoterol/Budesonide 12/400 mcg fix dose combination deliver via Discair® ( test product , n = 33 ) . Patients evaluate 4 consecutive visit : baseline ( enrollment ) , screen , treatment , end treatment ( 24h treatment ) . For newly diagnose formerly diagnosed patient COPD medication , screen visit perform day enrollment . For formerly diagnose patient receive COPD treatment , day screen visit base completion run-in period , length determine specific medication . During run-in period , salbutamol ( 100 μg inhaler ) prescribe rescue medication . Spirometric measurement ( FEV1 , FVC ) perform period 12 h 12 different time : pretreatment ( prior first dose ) posttreatment ( 15. min , 30. min , 1 hr , 2 hr , 3 hr , 4 hr , 5 hr , 6 hr , 8 hr , 10 hr 12 hr ) .</detailed_description>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Bronchodilator Agents</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<mesh_term>Budesonide</mesh_term>
	<criteria>Patients age ≥40 year newly formerly diagnose moderate severe COPD ( Patients postbronchodilator FEV1/FVC ratio &lt; 0.70 , FEV1 &lt; 80 % predict normal . Patients chronic cough chronic productive cough breathlessness even walk slowly along flat ground . ) Current smoker exsmokers smoke history least 10 packyears Patients exacerbation within last 4 week Females patient childbearing potential use effective birth control method Patients capability communicate investigator Patients accept comply requirement protocol Patients sign write informed consent prior participation Patients history hypersensitivity drug contain longacting beta2agonist corticosteroid Patients abnormal blood glucose level ( ( ≥140 mg/dl ) Patients unregulated diabetes mellitus Patients serum potassium level ≤3.5 mEq/L &gt; 5.5mEq/L Patients asthma Patients history myocardial infarction , severe hearth failure , acute ischemic coroner disease severe cardiac arrhythmia require treatment within least 6 week Patients lung cancer Patients vaccinate live attenuate vaccine within 2 week prior screen visit runin period . Patients COPD exacerbation lower respiratory track infection require antibiotic , oral parenteral corticosteroid treatment within 4 week prior screen visit runin period . Women pregnant nursing History allergic rhinitis atopy</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Formoterol</keyword>
	<keyword>Budesonide</keyword>
	<keyword>Dry powder inhalation</keyword>
	<keyword>Discair</keyword>
	<keyword>COPD</keyword>
</DOC>